HC Wainwright Issues Optimistic Forecast for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Research analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for shares of Corcept Therapeutics in a report released on Wednesday, February 25th. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology company will post earnings per share of ($0.40) for the quarter, up from their prior forecast of ($0.49). HC Wainwright currently has a “Buy” rating and a $67.00 target price on the stock. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.37 EPS, FY2026 earnings at $0.26 EPS, FY2027 earnings at $2.09 EPS, FY2028 earnings at $2.95 EPS and FY2029 earnings at $4.79 EPS.

A number of other research firms also recently issued reports on CORT. UBS Group began coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price objective on the stock. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 price target on the stock. in a research note on Wednesday, December 31st. Zacks Research lowered Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, January 13th. Canaccord Genuity Group raised their target price on Corcept Therapeutics from $99.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, January 23rd. Finally, Truist Financial set a $50.00 price target on Corcept Therapeutics in a report on Wednesday, December 31st. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $77.17.

Corcept Therapeutics Trading Down 0.2%

Corcept Therapeutics stock opened at $35.70 on Friday. Corcept Therapeutics has a 52-week low of $28.66 and a 52-week high of $117.33. The company has a market cap of $3.80 billion, a P/E ratio of 43.54 and a beta of 0.25. The company has a quick ratio of 3.07, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $44.41 and a two-hundred day simple moving average of $65.77.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13). Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. The firm had revenue of $202.13 million for the quarter, compared to analysts’ expectations of $254.94 million. During the same quarter last year, the company posted $0.26 EPS. The firm’s revenue was up 11.1% compared to the same quarter last year.

Insider Activity at Corcept Therapeutics

In other news, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $79.52, for a total value of $1,590,400.00. Following the transaction, the insider owned 7,904 shares of the company’s stock, valued at approximately $628,526.08. The trade was a 71.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Joseph K. Belanoff sold 40,000 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $79.77, for a total transaction of $3,190,800.00. Following the transaction, the chief executive officer owned 2,701,370 shares of the company’s stock, valued at approximately $215,488,284.90. This represents a 1.46% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 125,000 shares of company stock worth $8,301,450. 20.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its position in shares of Corcept Therapeutics by 18.9% in the first quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company’s stock worth $1,757,000 after buying an additional 2,444 shares in the last quarter. Amundi bought a new stake in Corcept Therapeutics in the 1st quarter worth approximately $450,000. NewEdge Advisors LLC purchased a new stake in shares of Corcept Therapeutics during the 1st quarter worth approximately $518,000. Sumitomo Mitsui Trust Group Inc. raised its holdings in shares of Corcept Therapeutics by 7.9% during the 2nd quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,129 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 230 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its position in shares of Corcept Therapeutics by 1.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 9,951 shares of the biotechnology company’s stock valued at $730,000 after acquiring an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company’s stock.

Trending Headlines about Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: HC Wainwright keeps a constructive stance — the firm retained a “Buy” rating and a $67 price target and revised some near-term quarterly EPS forecasts upward (Q1–Q3 adjustments), providing continued analyst support for the story. HC Wainwright Research Note
• Neutral Sentiment: Short-interest report shows no meaningful reported short position (entry shows 0 shares / 0.0 days), so today’s move is unlikely driven by short-covering or a jump in new short activity. (Data in the filing appears anomalous.)
• Neutral Sentiment: Market commentary and analysis pieces question whether current pricing fully reflects the stock’s steep one‑year decline and ongoing operational risks — useful background but not an immediate catalyst. Is Corcept Pricing Reflect Its Decline (Yahoo)
• Neutral Sentiment: Post‑earnings coverage and summaries highlight a mixed picture from the Q4 call (growth but rising risks); these recaps inform investor expectations but are not new filings. TipRanks Earnings Recap
• Negative Sentiment: Multiple securities class‑action suits and dozens of plaintiff‑solicitation notices were announced this week, alleging securities law violations for the period Oct 31, 2024–Dec 30/31, 2025. Several national firms are seeking lead plaintiffs (April 21, 2026 deadline), creating legal overhang, potential defense costs and settlement risk. Rosen Law Firm Notice Hagens Berman Alert
• Negative Sentiment: HC Wainwright lowered medium‑ and long‑term earnings forecasts (FY2026–FY2030 cuts across multiple years), signaling reduced analyst expectations for structural revenue/profitability growth; downward revisions can pressure valuation and investor confidence despite the maintained Buy rating. HC Wainwright Estimates Update

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.